№ files_lp_3_process_7_088011
File format: docx
Character count: 37304
File size: 412 KB
The document discusses the proposed changes to the 3GPP specifications for the cancellation of PUSCH repetitions and prioritization of dynamic and configured grants in the context of enhanced configured grant transmission for URLLC.
Year:
2020
Region / City:
e-Meeting, May 25th – June 5th
Theme:
Enhanced Configured Grant Transmission for URLLC
Document Type:
Email Discussion
Organization / Institution:
3GPP TSG RAN WG1
Author:
Chairman
Target Audience:
Members of 3GPP TSG RAN WG1
Period of Validity:
Until May 29th, 2020
Date of Approval:
May 25th, 2020
Date of Changes:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2022
Region / City:
Not specified
Topic:
Bone health, flavonoids, sea buckthorn
Document Type:
Research Table
Institution:
Not specified
Author:
Not specified
Target Audience:
Researchers in pharmacology, bone health, and phytochemistry
Period of Action:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Note:
Contextual description
Year:
2022
Region / city:
Online
Topic:
SL LBT failure detection and recovery procedure
Document Type:
Draft
Organization / institution:
3GPP TSG-RAN WG2
Author:
vivo (Rapporteur)
Target audience:
Industry professionals, telecommunications companies
Effective period:
October 2022
Approval date:
Not specified
Date of changes:
Not specified
Title:
The ARRIVE reporting checklist
Related guideline:
ARRIVE guidelines 2.0
Subject:
Reporting standards for in vivo animal research
Document type:
Reporting checklist
Scope:
Articles describing in vivo animal experiments
Sections:
Essential 10; Recommended Set
Items:
21 main items with sub-items
Key topics:
Study design; Sample size; Inclusion and exclusion criteria; Randomisation; Blinding/Masking; Outcome measures; Statistical methods; Experimental animals; Experimental procedures; Results; Ethical statement; Housing and husbandry; Animal care and monitoring; Interpretation; Generalisability; Protocol registration; Data access; Declaration of interests
Cited work 1:
The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research, PLOS Biology, 2020 Jul;18(7):e3000410
Cited work 2:
The ARRIVE reporting checklist, The EQUATOR Network reporting guideline platform, The UK EQUATOR Centre, 2025
Authors cited:
Sert NP; Hurst V; Ahluwalia A; Alam S; Avey MT; Baker M; et al.
Intended users:
Authors preparing manuscripts on animal research
Purpose:
To document adherence to reporting standards in animal experiments
Year:
2021
Region / city:
Not specified
Topic:
eDRX cycles
Document Type:
Draft
Organization / Institution:
3GPP TSG-RAN WG2
Author:
vivo, Qualcomm, OPPO, Huawei, HiSilicon, Xiaomi, Samsung, LGE
Target audience:
Members of the 3GPP working groups
Period of validity:
August 2021
Approval Date:
Not specified
Date of changes:
Not specified
Year:
2026
Region / City:
Seoul, Korea
Topic:
Medical Research, Genome Editing, Ophthalmology
Document Type:
Research Article
Organization / Institution:
Seoul National University Hospital, Seoul National University College of Medicine
Author:
Jeong Hun Kim
Target Audience:
Researchers, Clinicians, Medical Professionals
Period of Effect:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Contextual Description:
Research article presenting recent experimental results and clinical trial preparations regarding in vivo genome editing for treating vision-threatening retinopathies, such as AMD, DR, and ROP.
In Vivo Anti-Inflammatory and Anti-Nociceptive Activities of Aerial Part Extracts of Zehneria scabra
Year:
Not specified
Journal:
International Journal of Pharmacy and Industrial Research
ISSN (Print):
2231–3648
ISSN (Online):
2231–3656
Article Type:
Research Article
Author:
Baye Akele
Affiliation:
University of Gondar, College of Medicine and Health
Address:
P.O Box 196, Gondar, Ethiopia
Email:
[email protected]
Study Subject:
Zehneria scabra (Cucurbitaceous family)
Study Design:
In vivo experimental study
Experimental Models:
Acetic acid–induced writhing test; Carrageenan-induced inflammation
Extraction Method:
80% methanol extraction by maceration
Test Organisms:
Swiss albino mice (18–25 g)
Region of Plant Collection:
North east Ethiopia
Plant Identification Repository:
National Herbarium, Botanic Laboratory, Addis Ababa University, Ethiopia
Keywords:
Antinociceptive, Anti-inflammatory, Zehneria scabra, Maceration
Year:
2023
Region / city:
N/A
Subject:
Immunology, Cell Biology
Document type:
Supplementary Table
Organization:
N/A
Author:
N/A
Target audience:
Researchers, scientists in immunology and cell biology
Period of validity:
N/A
Approval date:
N/A
Date of changes:
N/A
Year:
2014
Region / City:
Pittsburgh, PA, USA
Subject:
Government procurement of imaging and laboratory equipment
Document Type:
Contract amendment / solicitation modification
Issuing Agency:
U.S. Department of Veterans Affairs, Veterans Health Administration, Service Area Office East
Contractor:
Bruker Biospin Corp.
Contracting Officer:
Travis Gibbons
Effective Date:
25-Jul-2014
Solicitation Number:
VA268-14-Q-0031
Amendment Number:
1
Equipment Included:
In Vivo Xtreme Imaging System, Multimodal Animal Rotation System (MARS), Anesthesia System, Bone Density Software Module
Purpose:
Correct description of line item 1 and update price schedule
Key Features:
Fluorescence and bioluminescence imaging, multi-animal anesthesia, skeletal X-ray co-localization, high-resolution camera, software upgradability, PET/SPECT imaging, multi-angle imaging without handling animals
Exempt Distribution of Carbon14 Urea Capsules for In Vivo Diagnostic Use in Humans, Effective 1/2/98
Year:
1998
Agency:
U.S. Nuclear Regulatory Commission
Document Type:
Federal Regulation / Rule
Subject:
Radioactive Drugs, Licensing Exemptions
RATS ID:
19977
Effective Date:
1/2/1998
CFR Sections:
30.21, 32.21, 32.21a
Usage Restrictions:
In vivo diagnostic use for humans only; not for research involving human subjects; not for incorporation into food, beverages, cosmetics, or other drugs
License Requirements:
Specific license required for commercial distribution, manufacture, or research use
Labeling Requirements:
Must indicate radioisotope, physical/chemical form, activity, and usage restrictions
Year:
2016
Institution:
University of Wisconsin–Madison
Document type:
Request for Bid / Contract Solicitation
Contract number:
17-5725-R1
Issue date:
8/17/16
Due date:
8/31/16, 2:00 PM CDT
Agent:
Janet Bresnahan
Scope:
In Vivo Drug Discovery Pharmacology Assays, Pharmacokinetics and Dose Tolerability in Rodents
Contract duration:
One year from award, automatically renewable for two additional one-year terms
Bid submission requirements:
Hard copy, CD/DVD/Flash drive, signatures required
Applicable rules:
Federal procurement rules, University standard terms and conditions
Sections included:
Submittal Instructions, General Information, RFB Process Instructions, Bidder Qualifications, Performance and Contract Requirements, Attachments A–H
Audience:
Potential vendors and contractors for pharmacology research services
Contextual description:
Official bid solicitation detailing requirements, procedures, and conditions for vendors to provide in vivo pharmacology testing services at the University of Wisconsin–Madison under a specified contract.
Year:
2016
Region / City:
Shanghai, China; Shenzhen, China; Suzhou, China; Helsinki, Finland; Turku, Finland
Subject:
Tissue engineering, vascularization, skin flap regeneration
Document Type:
Peer-reviewed research article
Institution / Organization:
Shanghai Ninth People’s Hospital, Xi’an Jiaotong University, Shenzhen Institutes of Advanced Technology, University of Helsinki, Soochow University, Åbo Akademi University
Authors:
Xiaoming Sun, Qi Lang, Hongbo Zhang, Liying Cheng, Ying Zhang, Guoqing Pan, Xin Zhao, Huilin Yang, Yuguang Zhang, Hélder A. Santos, Wenguo Cui
Target Audience:
Researchers in biomedical engineering and regenerative medicine
Methodology:
Electrospinning of photocrosslinkable gelatin methacryloyl (GelMA) hydrogels
Key Findings:
Enhanced endothelial cell adhesion, proliferation, migration, tubulogenesis, and increased skin flap survival in rat models
Publication DOI:
10.1002/adfm.201604617
Access:
Non-commercial use under Wiley Terms and Conditions
Year:
2023
Region / City:
Not specified
Topic:
Fetal cardiac function, hypoxic pregnancy, echocardiography
Document type:
Scientific research article
Institution:
Not specified
Authors:
Patey, KL Botting, Y Niu, L Zhang, J Ma, SG Ford, W Tong, CM Coutinho, B Thilaganathan, DA Giussani
Target audience:
Researchers, clinicians, scientists in the field of prenatal health, cardiology, and animal models
Period of validity:
Not specified
Approval date:
Not specified
Date of revisions:
Not specified
Year:
2025
Location:
Dallas, USA
Type of document:
Draft technical report
Organization:
3GPP TSG RAN WG1
Author:
Moderator (MediaTek)
Agenda item:
10.2.2
Purpose:
Discussion and decision on enhancing DL CSI acquisition
Target audience:
Companies participating in 3GPP RAN1 discussions
Related contributions:
38 company inputs summarized
Period:
November 17–21, 2025
Date of draft:
2025-11-17
Meeting:
3GPP TSG RAN WG1 #112
Document number:
R1-2301247
Location:
Athens, Greece
Dates:
February 27 – March 3, 2022
Agenda item:
9.1.2
Source:
Moderator (Samsung)
Release:
3GPP Release 18
Scope:
NR Evolved MIMO CSI enhancements
Frequency range:
FR1
Technical focus:
CSI reporting, Type-II codebook refinement, Coherent-JT, multi-TRP
Assumptions:
Ideal backhaul and synchronization
Participating companies:
Samsung, Huawei, ZTE, Ericsson, Nokia/NSB, Apple, Qualcomm, MediaTek, Intel, vivo, OPPO, and others
Decision status:
Discussion and decision with partial agreements and open issues
Year:
2022
Event:
3GPP TSG RAN WG1 #108-e e-Meeting
Date:
February 21 – March 3, 2022
Source:
Moderator (CATT)
Title:
Moderator summary #1 on enhancements of beam management for multi-TRP
Agenda Item:
8.1.2.3
Document Type:
Discussion and Decision
Participants:
Qualcomm, LGE, CMCC, Xiaomi, Lenovo, Motorola Mobility, Intel, TCL, Sony, OPPO, Apple, ZTE, Samsung, MTK, vivo, Spreadtrum, CATTA, FutureWei
Topics Covered:
Beam measurement/reporting, L1-SINR reporting, CSI-RS configuration, TRP-specific BFR, M-TRP beam failure recovery
Standards Referenced:
3GPP 38.214
Document Scope:
Issues and proposals on enhancements for beam management in multi-TRP scenarios
Note:
Year
Subject area:
Education
Document type:
Role description
Organization / institution:
Pearson
Target audience:
Candidates, educators
Context:
Job description for a BTEC Tech Awards Moderator, outlining key responsibilities and qualifications required.
Year:
2025
Region / City:
Dallas, USA
Theme:
AI/ML, 6GR
Document Type:
Summary
Organization / Institution:
3GPP
Author:
Samsung
Target Audience:
RAN Working Group 1
Period of validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2024
Region / city:
Fukuoka, Japan
Theme:
CSI enhancement, NR MIMO, codebook refinement
Document type:
Discussion and Decision
Organization / institution:
3GPP TSG RAN WG1
Author:
Moderator (Samsung)
Target audience:
3GPP participants
Period of validity:
May 20th – 24th, 2024
Approval date:
N/A
Modification date:
N/A
Year:
2024
Region / City:
Changsha, Hunan Province, China
Topic:
CSI-RS ports, NR MIMO, FR1, Type-I codebook refinement
Document Type:
Report
Organization / Institution:
3GPP TSG RAN WG1
Author:
Moderator (Samsung)
Target Audience:
Technical experts, industry professionals in wireless communication
Period of validity:
April 15th – 19th, 2024
Date of approval:
N/A
Date of modifications:
N/A